Home›Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide›Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide + Triazolam

Does Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Interact with Triazolam?

Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Triazolam have a contraindicated drug interaction according to U.S. FDA drug labeling data. Sedatives/hypnotics: orally administered midazolam, triazolam ↑ midazolam ↑ triazolam Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Class
Cytochrome P450 3A Inhibitor
Triazolam Class
Benzodiazepine
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and your doctor is considering prescribing Triazolam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide(Symtuza)+💊 Triazolam(Halcion)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Cytochrome P450 3A Inhibitor
Drug B class
Benzodiazepine
Source
FDA drug label - darunavir, cobicistat, emtricitabine, and tenofovir alafenamide

What this means in plain English

Sedatives/hypnotics: orally administered midazolam, triazolam ↑ midazolam ↑ triazolam Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.

About Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Triazolam

Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide is a Cytochrome P450 3A Inhibitor, while Triazolam is a Benzodiazepine. You may recognize them by the brand names Symtuza and Halcion. Both medications are taken by mouth. Both Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Triazolam carry an FDA boxed warning — the agency's most serious safety designation.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Triazolam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.